Press Releases

Tango Therapeutics Appoints Mace Rothenberg, MD, and Lesley Ann Calhoun, CPA, to Board of Directors

CAMBRIDGE, Mass. March 24, 2021 – Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointments of Mace Rothenberg, MD, and Lesley Ann Calhoun, CPA, to its Board of Directors. Dr. Rothenberg has over 30 years of global clinical leadership and strategic expertise, having most recently served as the Chief Medical Officer at Pfizer. Ms. Calhoun is an experienced biotech finance leader who currently serves as Chief Financial Officer at Aligos Therapeutics.

“The addition of Dr. Mace Rothenberg to our Board of Directors brings strategic insights, and portfolio and clinical development expertise, just as we advance our lead program into IND-enabling studies and clinical development,” said Barbara Weber, MD, President and Chief Executive Officer of Tango. “The addition of Lesley Ann Calhoun brings us significant financial acumen and a broad range of experiences with companies at various stages, which will be very valuable as we continue to grow.”

Dr. Mace Rothenberg, the outgoing Chief Medical Officer at Pfizer, has chaired and served on multiple committees responsible for research investment, medical integrity, and determination of product benefit-risk. He created a global infrastructure for overseeing medical reporting to regulatory organizations, and established several programs focused on improving medical decision making for the company. Dr. Rothenberg has deep experience in clinical development strategy, having guided eleven cancer medications to FDA approval. He is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer for his success in cancer drug development, the Lane W. Adams Quality of Life Award from the American Cancer Society, and the Statesman Award from the American Society of Clinical Oncology.

Lesley Ann Calhoun currently serves as Executive Vice President and Chief Financial Officer at Aligos Therapeutics. She has significant expertise in the creation and implementation of global financial management strategies and is responsible for oversight of all financial aspects of the company’s transition from a research organization to clinical development and ultimately to commercialization. During her tenure, she has led the company’s capital market activities, cultivating critical relationships with banks and is responsible for all investor relations, financial planning/analysis, accounting, compliance, and risk management activities. Prior to Aligos, Ms. Calhoun served as Senior Vice President of Finance & Administration and Chief Accounting Officer at Global Blood Therapeutics, where she led financial and accounting functions for the company’s transition from private to public, and development stage to commercialization of products for orphan diseases.

About Tango Therapeutics

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine to people with cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at key drivers in cancer. The company is focused on counteracting tumor suppressor gene loss and reversing the ability of cancer cells to evade the immune system. For more information, please visit www.tangotx.com.

Tango Contact:

Daniella Beckman
Chief Financial Officer
info@tangotx.com

Investor Contact:

Sam Martin
Argot Partners
tango@argotpartners.com

Media Contact:

Joshua R. Mansbach
Argot Partners
tango@argotpartners.com

Connect with us on LinkedIn to learn more about Tango.